NCT00087659
Completed
N/A
A Prostate Cancer Study in Men Undergoing Androgen Deprivation Therapy
ConditionsProstate Cancer
Drugszoledronic acid
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Prostate Cancer
- Sponsor
- Novartis Pharmaceuticals
- Locations
- 15
- Primary Endpoint
- Percent change in bone mineral density of the lumbar spine (L2-L4) at 6 and 12 months.
- Status
- Completed
- Last Updated
- 16 years ago
Overview
Brief Summary
This study is being conducted to compare the effect of an investigational drug versus placebo on bone loss in men with prostate cancer who are receiving Androgen Deprivation Therapy (ADT). The study drug or placebo will be administered every three months of four treatments in one year.
In order to participate, male patients 18 years and older must be consecutive veterans from participating Veterans Administration Medical Centers.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Signed informed consent
- •Age \> 18 years
- •Histologically confirmed diagnosis of carcinoma of the prostate
- •No distant metastases at the start of ADT and continuously low PSA (\<2.0) on continuous ADT (stage Tany Nany MO).
- •Patients initiating or receiving ADT with a LHRH agonist (with or without an antiandrogen) and with the intended duration of ADT of at least 12 months at the time of randomization. Patients undergoing bilateral orchiectomy or with history of this procedure are also eligible.
- •Patient with a baseline BMD T-score at or above -2.0 standard deviations in the lumbar spine (L2-L4) and the total hip are eligible
- •Life expectancy of at least 12 months
- •Zubrod performance status of 0, 1, or 2
Exclusion Criteria
- •Patients who received any prior bisphosphonate therapy in the past 6 months
- •Metabolic bone disease including Paget's disease or hyperparathyroidism
- •Radiographic evidence of bone metastases
- •Patients who have received prior treatment with systemic corticosteroids within the past 12 months (short term corticosteroid therapy, e.g. to prevent/treat chemotherapy-induced nausea/vomiting or for acute illness like asthma exacerbation, is acceptable)
- •Patients with prior exposure to anabolic steroids or growth hormone within the past 6 months
- •Current treatment with estrogen or complementary medicines known to contain estrogens
- •Patients with clinical or radiological evidence of existing fracture in the lumbar spine and/or total hip
- •Patients with a history of fracture with low-intensity or no associated trauma
- •Patients with any prior treatment for osteoporosis
- •Patients with previous or concomitant malignancy within the past 5 years except adequately treated basal or squamous cell carcinoma of the skin, and colonic polyps with non-invasive malignancy which have been removed
Outcomes
Primary Outcomes
Percent change in bone mineral density of the lumbar spine (L2-L4) at 6 and 12 months.
Secondary Outcomes
- Percent change in bone mineral density of the total hip (including femoral neck, trachanteric region, and Ward's triangle) following one year of therapy.
Study Sites (15)
Loading locations...
Similar Trials
Completed
Phase 2
A Phase 2 Study With Enzastaurin Plus Chemotherapy or Placebo Plus Chemotherapy for Prostate Cancer PatientsProstate CancerNCT00466440Eli Lilly and Company108
Unknown
Phase 3
Androgen Suppression Combined With Elective Nodal and Dose Escalated Radiation TherapyProstate CancerNCT00175396University of British Columbia400
Completed
Phase 4
A Study of Tadalafil After Radical ProstatectomyErectile DysfunctionNCT01026818Eli Lilly and Company583
Terminated
Phase 2
Testosterone Replacement in Men With Non-Metastatic Castrate Resistant Prostate CancerProstate CancerNCT00515112University of Chicago6
Completed
N/A
A Pilot Study of Parenteral Testosterone and Oral Etoposide as Therapy for Men With Castration Resistant Prostate CancerProstate CancerNCT01084759Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins16